Taurolin®-Gel

Product Information

Live-saving antibacterial for severe abdominal sepsis and peritonitis. For severe surgical infections and use in surgical oncology.

Chemistry

Taurolidine, the active substance of Taurolin®, is derived from the naturally occurring endogenous aminosulphonic acid taurine.

Product properties

Active against aerobic and anaerobic, gram-positive and gram-negative bacteria, mycobacteria, and fungi (prevents secondary Candida colonization). Prevents adherence of microorganisms. Bacterial resistance unlikely to occur due to unique mechanism of action. Active against MRSA, ORSA, VRE, VISA, and VRSA.

Antitoxin activity

• No Endotoxins release.
• Inactivates exotoxins.
• Anti-mediator therapy: Down-regulates increased cytokines
• TNF-α, IL-1, and IL-6 to normal levels.

Anti-neoplastic activity

• Highly active against a variety of animal and human tumor cell lines.
• Modulation of peri-operative pro-inflammatory responses and
• promotion of anti-tumor responses.
• Reduction of adherence and growth of micro-metastases in the peri- and post-operative period.

Safety, Tolerability and Compatibility

Very low toxicity. LD50 in all species and with all applications far above 1,000 mg/kg BW.

No mutagenic, embryotoxic, or teratogenic effects and no cytotoxicity or ototoxicity.

No general pharmacological and pharmacodynamical actions. Favourable clinical safety profile based on experience with aprox. 14,000 patients, well established for local i.p. and experimental i.v. treatment of abdominal sepsis, peritonitis and pancreatitis, catheter sepsis, osteitis and prevention of adherence and growth of tumor metastases.

Only minor local and no systemic clinically relevant adverse events after correct administration.

Compatible with many parenterals.

Can be combined with all conventional antibiotics.

Therapeutical benefits

Reduces mortality and morbidity in patients with surgical infections, abdominal sepsis and peritonitis. Prevents adherence and growth of metastases and stops or reduces tumor progression. Practically no adverse events.